BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a sell rating to a hold rating in a research note issued to investors on Wednesday.

RARE has been the topic of a number of other reports. Canaccord Genuity set a $80.00 target price on shares of Ultragenyx Pharmaceutical and gave the company a buy rating in a report on Thursday, November 16th. Robert W. Baird dropped their target price on shares of Ultragenyx Pharmaceutical from $85.00 to $80.00 and set an outperform rating on the stock in a report on Friday, November 3rd. Zacks Investment Research cut shares of Ultragenyx Pharmaceutical from a hold rating to a sell rating in a report on Wednesday, October 25th. Morgan Stanley reiterated an equal weight rating and issued a $71.00 price target (up previously from $69.00) on shares of Ultragenyx Pharmaceutical in a research note on Friday, October 6th. Finally, Credit Suisse Group assumed coverage on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 17th. They issued an outperform rating and a $67.00 price target on the stock. Nine equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $72.06.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at $56.84 on Wednesday. The stock has a market cap of $2,714.49, a PE ratio of -8.15 and a beta of 1.83. Ultragenyx Pharmaceutical has a fifty-two week low of $43.14 and a fifty-two week high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($1.87). The firm had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.02 million. The firm’s revenue for the quarter was up 81.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.64) earnings per share. equities analysts predict that Ultragenyx Pharmaceutical will post -7.31 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at about $156,000. Kazazian Asset Management LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $213,000. Fox Run Management L.L.C. acquired a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $213,000. Ameritas Investment Partners Inc. grew its position in shares of Ultragenyx Pharmaceutical by 7.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,474 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 248 shares in the last quarter. Finally, Amalgamated Bank grew its position in shares of Ultragenyx Pharmaceutical by 7.6% during the 2nd quarter. Amalgamated Bank now owns 4,980 shares of the biopharmaceutical company’s stock worth $309,000 after purchasing an additional 352 shares in the last quarter. Institutional investors and hedge funds own 94.10% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/28/ultragenyx-pharmaceutical-rare-raised-to-hold-at-bidaskclub.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.